Equity Overview
Price & Market Data
Price: $8.01
Daily Change: -$0.085 / 1.06%
Range: $7.92 - $8.06
Market Cap: $1,094,534,528
Volume: 556,378
Performance Metrics
1 Week: 4.24%
1 Month: -7.79%
3 Months: -0.44%
6 Months: 11.51%
1 Year: 58.32%
YTD: -10.97%
Company Details
Employees: 130
Sector: Health technology
Industry: Biotechnology
Country: Canada
Details
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.